February 21st, 2011
Posted by Shane Climie, Ph.D.
Sometimes, between the hotel room, the lectures, the networking, the power lunches and the data consumption at a conference, you’re on the plane home before you have time to reflect upon why you attended in the first place. I’m excited to be heading to the 18th International Molecular Medicine Tri-Conference in San Francisco this week—and I’m setting out my reasons for going this year beforehand.
I always look forward to this conference because of its balanced range of life science topics, including those with technical, scientific, business, strategy, regulatory and reimbursement slants. Within this balanced range of topics, the Tri-Con uses a channel structure to help attendees “tune in” where they can get the biggest bang for their buck. I’m excited to learn more about the following specifics within each channel:
- Diagnostics—Rapid changes are taking place on the diagnostics stage this year. Personally, I’m interested in molecular diagnostics, personalized diagnostics, cancer markers and circulating tumor cells (CTCs). I’ll be tuning in to discussions on the adoption and integration of the next generation of sequencing, companion diagnostics and the use of/characterization of CTCs.
- Drug discovery & development–Here, sessions promise updates on translational science, including the use of biomarker technology to support drug development. Read the rest of this entry »
Tags: 18th international molecular tri-conference, biologics, cancer markers, ctcs, diagnostics, drug discovery, Health Care, informatics, life sciences, medical devices, personalized diagnostics, tri-con
Posted in Our News | No Comments »